- Home
- ETON vs EVGO Comparison
ETON vs EVGO Comparison
Compare ETON & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- EVGO
- Stock Information
- Founded
- ETON 2017
- EVGO 2010
- Country
- ETON United States
- EVGO United States
- Employees
- ETON N/A
- EVGO N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- EVGO Other Specialty Stores
- Sector
- ETON Health Care
- EVGO Consumer Discretionary
- Exchange
- ETON Nasdaq
- EVGO Nasdaq
- Market Cap
- ETON 329.8M
- EVGO N/A
- IPO Year
- ETON 2018
- EVGO N/A
- Fundamental
- Price
- ETON $13.74
- EVGO $2.85
- Analyst Decision
- ETON Strong Buy
- EVGO Strong Buy
- Analyst Count
- ETON 3
- EVGO 10
- Target Price
- ETON $27.67
- EVGO $6.11
- AVG Volume (30 Days)
- ETON 232.5K
- EVGO 4.2M
- Earning Date
- ETON 03-18-2025
- EVGO 03-04-2025
- Dividend Yield
- ETON N/A
- EVGO N/A
- EPS Growth
- ETON N/A
- EVGO N/A
- EPS
- ETON N/A
- EVGO N/A
- Revenue
- ETON $39,011,000.00
- EVGO $256,825,000.00
- Revenue This Year
- ETON $107.69
- EVGO $42.11
- Revenue Next Year
- ETON $65.50
- EVGO $30.36
- P/E Ratio
- ETON N/A
- EVGO N/A
- Revenue Growth
- ETON 23.29
- EVGO 59.56
- 52 Week Low
- ETON $3.03
- EVGO $1.65
- 52 Week High
- ETON $18.41
- EVGO $9.07
- Technical
- Relative Strength Index (RSI)
- ETON 41.63
- EVGO 54.03
- Support Level
- ETON $12.73
- EVGO $2.62
- Resistance Level
- ETON $15.10
- EVGO $3.06
- Average True Range (ATR)
- ETON 0.98
- EVGO 0.16
- MACD
- ETON -0.05
- EVGO 0.08
- Stochastic Oscillator
- ETON 33.67
- EVGO 72.11
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.